Pharmaceutical - Xalkori

Filter

Current filters:

Xalkori

Popular Filters

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

Pfizer’s Xalkori gains regular FDA approval for NSCLC

Pfizer’s Xalkori gains regular FDA approval for NSCLC

22-11-2013

The US Food and Drug Administration yesterday (November 21) granted pharma behemoth Pfizer’s Xalkori…

North AmericaOncologyPfizerPharmaceuticalRegulationXalkori

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

NICE says Xalkori is not cost effective in ALK-positive NSCLC

20-08-2013

US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…

EuropeOncologyPfizerPharmaceuticalPricingRegulationXalkori

Conditional European approval for Pfizer's Xalkori

25-10-2012

The European Commission yesterday gave conditional marketing authorization for global drugs behemoth…

EuropeOncologyPfizerPharmaceuticalRegulationXalkori

ESMO 2012 Congress highlights

01-10-2012

The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

Pfizer and Roche hope to score with ESMO presentations, notes GlobalData

25-09-2012

The European Society for Medical Oncology (ESMO) will kick off its 2012 annual meeting on Friday, September…

BiotechnologyHerceptinOncologyPfizerPharmaceuticalResearchRocheXalkori

Back to top